

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**April 2, 2026**

---

**I New Study - Initial Review**

**NRG-GY038**, A Randomized Phase II Trial of Sacituzumab Govitecan-hziy (SG) and Bevacizumab versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer that has Progressed on Prior Maintenance PARP Inhibitor Therapy (Version Date 03/02/26)

---

**II Continuing Review**

**A031803**, Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (Version Date 04/23/25)

---

**III Continuing Review**

**CALGB-100104**, A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813, IND#70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma (Version Date 09/27/19)

---

**IV Continuing Review**

**CCTG MA.39**, Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer (Version Date 09/19/22)

---



## **V Continuing Review**

**NRG-GI006**, Phase III Randomized Trial of Proton Beam Therapy (PBT) versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer (Version Date 07/02/25)

---